ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma

Published:2021-04 Issue:4 Volume:74 Page:893-906
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Arechederra Maria,Bazai Sehrish K.^ORCID,Abdouni Ahmed,Sequera Celia^ORCID,Mead Timothy J.,Richelme Sylvie,Daian Fabrice,Audebert Stéphane,Dono Rosanna^ORCID,Lozano Anthony,Gregoire Damien,Hibner Urszula,Allende Daniela S.,Apte Suneel S.^ORCID,Maina Flavio^ORCID

Funder

Canceropôle PACA

Fondation pour la Recherche Médicale

Paul G. Allen Frontiers Group

American Heart Association

Institut National Du Cancer

Higher Education Commission, Pakistan

Association pour la Recherche sur le Cancer

Fondation de France

Publisher

Elsevier BV

Subject

Hepatology

Reference33 articles.

1. Epidemiology of hepatocellular carcinoma;McGlynn;Hepatology,2020

2. A global view of hepatocellular carcinoma: trends, risk, prevention and management;Yang;Nat Rev Gastroenterol Hepatol,2019

3. Hepatocellular carcinoma;Villanueva;New Engl J Med,2019

4. Advances in targeted therapies for hepatocellular carcinoma in the genomic era;Llovet;Nat Rev Clin Oncol,2015

5. Genetic landscape and biomarkers of hepatocellular carcinoma;Zucman-Rossi;Gastroenterology,2015

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small-molecule-based targeted therapy in liver cancer;Molecular Therapy;2024-08

2. New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma;Drug Discovery Today;2024-08

3. Advances in hepatocellular carcinoma drug resistance models;Frontiers in Medicine;2024-07-31

4. TMB Signature-Related RCAN2 Promotes Apoptosis by Upregulating EHF/DR5 Pathway in Hepatocellular Carcinoma;Frontiers in Bioscience-Landmark;2024-07-02

5. Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy;Liver International;2024-05-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3